Skip to content

Effectiveness and safety of dapsone 5% versus clindamycin 1% in the treatment of mild to moderate pimples

A randomised, double blind, comparative clinical trial assessing the effectiveness and safety of dapsone 5% versus clindamycin 1% in the treatment of mild to moderate acne vulgaris - DCRCT

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/08/009582
Enrollment
56
Registered
2017-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- All the patients, aged 12 to 42 years of either sex, presenting with mild to moderate acne(â?¥ 2 but â?¤ 30 total lesions ).

Interventions

Intervention1: Dapsone 5% gel: Patients were instructed to apply thin layer of dapsone 5% gel over the lesion twice daily for 12 weeks after rinsing the face and drying Control Intervention1: Clindamy

Sponsors

Medical College Kolkata
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects of 12 to 40 years of age of either sex 2.Mild to moderate acne: >= 2 but 3.Lesions in the face which correspond to a baseline investigator global assessment (IGA) score of 2 or 3

Exclusion criteria

Exclusion criteria: 1.Age 40 2.Total lesion count 30, 3.Subjects regularly using any anti-acne medications in the last 30 days before study entry 4.Severe acne: Subjects with nodulo-cystic lesions, acne conglobata, acne fulminans 5.Pregnancy or intention of pregnancy and breastfeeding 6.Patients with G6PD deficiency 7.History of having taken any medication that could interact with dapsone (e.g. Trimetoprim-sulfametoxazol 8.Known hypersensitivity to the study medication 9.Patients not willing to comply with protocol requirements

Design outcomes

Primary

MeasureTime frame
A. To compare the effectiveness of topical dapsone 5% gel and clindamycin 1% gel in the treatment of acne vulgaris. 1.By Global acne assessment scale 2. By no. of acne lesion 3. By size of acne lesion B. To compare the safety of above mentioned regime 1. By laboratory method 2. By checklist adverse effectsTimepoint: A. Baseline, end of 4th, 8th and 12th week B. Baseline and post treatment value

Secondary

MeasureTime frame
â?¢To assess the improvement in quality of life with the two treatment regimeTimepoint: baseline and end of 12th week

Countries

India

Contacts

Public ContactDr Amrita Sil

Paikpari Rural Hospital, Kolaghat

tks.nrs@gmail.com9433543508

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026